Oxford BioDynamics (LON:OBD) Trading 18.3% Higher – Still a Buy?

Oxford BioDynamics Plc (LON:OBD) shares traded up 18.3% during mid-day trading on Wednesday . The stock traded as high as GBX 0.20 and last traded at GBX 0.20. 1,739,901 shares were traded during mid-day trading, a decline of 88% from the average session volume of 15,004,250 shares. The stock had previously closed at GBX 0.17.

Oxford BioDynamics Stock Up 18.3%

The stock has a market capitalization of £8.58 million, a price-to-earnings ratio of -0.25 and a beta of 0.42. The firm’s fifty day moving average is GBX 0.20 and its 200-day moving average is GBX 0.24. The company has a debt-to-equity ratio of 457.97, a current ratio of 0.88 and a quick ratio of 2.80.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.